Cytosorbents Corp
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Arrangements
No director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408 during the quarter ended June 30, 2026.
Nasdaq Listing Compliance
On June 29, 2026, the Company received a letter from the Staff of Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(2) because the Company’s minimum MVLS was below the Nasdaq MVLS Requirement of $35 million. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until December 28, 2026, to regain compliance with the MVLS Requirement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.